GlaxoSmithKline (GSK) Share Forecast & Price Target

Compare

951 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GSK Analyst Ratings

Hold

2 Buy

8 Hold

4 Sell

Based on 14 analysts giving stock ratings to

GlaxoSmithKline

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GSK Stock 12 Month Forecast

Average Price Target

1,515.42p

▲(8.67%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is 1,515.42p with a high forecast of 2,290.00p and a low forecast of 1,170.00p. The average price target represents a 8.67% change from the last price of 1,394.50p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1169":"1,169p","1730":"1,730p","2291":"2,291p","1449.5":"1,449.5p","2010.5":"2,010.5p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.29K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1515.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.52K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.17K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1169,1449.5,1730,2010.5,2291],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1517,1576.4615384615386,1635.923076923077,1695.3846153846155,1754.8461538461538,1814.3076923076924,1873.7692307692307,1933.2307692307693,1992.6923076923076,2052.153846153846,2111.6153846153848,2171.076923076923,2230.5384615384614,{"y":2290,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1517,1516.8784615384616,1516.7569230769232,1516.6353846153847,1516.513846153846,1516.3923076923077,1516.2707692307692,1516.1492307692308,1516.0276923076924,1515.906153846154,1515.7846153846153,1515.663076923077,1515.5415384615385,{"y":1515.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1517,1490.3076923076924,1463.6153846153845,1436.923076923077,1410.2307692307693,1383.5384615384614,1356.8461538461538,1330.1538461538462,1303.4615384615386,1276.7692307692307,1250.076923076923,1223.3846153846152,1196.6923076923076,{"y":1170,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1691.24,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1460.99,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1460.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1595.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1470.49,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1371.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1310.96,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1315.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1373.02,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1449.25,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1451.72,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1445.79,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1517,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target2,290p

Average Price Target1,515p

Lowest Price Target1,170p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

1,572p

Buy

12.73%

Upside

Reiterated

06/25/25

GlaxoSmithKline's overall score reflects strong financial stability and strategic initiatives in specialty medicines, despite technical challenges. The company's focus on shareholder value through dividends and buybacks supports its current valuation, while recent earnings calls indicate a positive outlook for future growth.

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

1,450p

Hold

3.98%

Upside

Reiterated

06/24/25

Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Rajan SharmaGoldman Sachs

Goldman Sachs

―

Hold

―

Reiterated

06/19/25

GlaxoSmithKline (GSK) Gets a Hold from Goldman Sachs

James GordonJ.P. Morgan

J.P. Morgan

1,460p

Sell

4.70%

Upside

Reiterated

06/10/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)

Justin SmithBernstein

Bernstein

2,290p

Buy

64.22%

Upside

Reiterated

06/04/25

Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)

Kerry HolfordBerenberg Bank

Berenberg Bank

1,600p

Hold

14.74%

Upside

Downgraded

06/02/25

Berenberg Bank downgrades GlaxoSmithKline (GSK) to a Hold

Emily FieldBarclays

Barclays

1,450p

Hold

3.98%

Upside

Reiterated

05/15/25

Barclays Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Sarita KapilaMorgan Stanley

Morgan Stanley

14.5p→1,355p

Sell

-2.83%

Downside

Reiterated

05/07/25

GSK price target lowered to 1,355 GBp from 1,450 GBp at Morgan StanleyGSK price target lowered to 1,355 GBp from 1,450 GBp at Morgan Stanley

Graham ParryBank of America Securities

Bank of America Securities

1,510p

Sell

8.28%

Upside

Reiterated

04/30/25

GlaxoSmithKline Faces Sell Rating Amid EPS Decline and Pipeline Concerns

David EvansKepler Capital

Kepler Capital

1,500p

Hold

7.57%

Upside

Reiterated

04/30/25

GlaxoSmithKline (GSK) Gets a Hold from Kepler Capital

Jo WaltonUBS

UBS

1,600p

Hold

14.74%

Upside

Reiterated

04/30/25

GlaxoSmithKline (GSK) Gets a Hold from UBS

Benjamin Jackson CFAJefferies

Jefferies

1,450p

Hold

3.98%

Upside

Reiterated

04/30/25

Jefferies Remains a Hold on GlaxoSmithKline (GSK)

Unknown AnalystShore Capital

Not Ranked

Shore Capital

―

Buy

―

Reiterated

04/30/25

Rajesh KumarHSBC

HSBC

1,190p→1,170p

Sell

-16.10%

Downside

Reiterated

04/28/25

GSK price target lowered to 1,170 GBp from 1,190 GBp at HSBCGSK price target lowered to 1,170 GBp from 1,190 GBp at HSBC

Peter VerdultExane BNP Paribas

Exane BNP Paribas

1,350p

Hold

-3.19%

Downside

Initiated

04/16/25

BNP Paribas Exane Starts GlaxoSmithKline (GSK:LN) (GSK) at NeutralBNP Paribas Exane analyst Peter Verdult initiates coverage on GlaxoSmithKline (GSK:LN) (NYSE: GSK) with a Neutral rating and a price target of INR13.50.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

1,572p

Buy

12.73%

Upside

Reiterated

06/25/25

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

1,450p

Hold

3.98%

Upside

Reiterated

06/24/25

Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Rajan SharmaGoldman Sachs

Goldman Sachs

―

Hold

―

Reiterated

06/19/25

GlaxoSmithKline (GSK) Gets a Hold from Goldman Sachs

James GordonJ.P. Morgan

J.P. Morgan

1,460p

Sell

4.70%

Upside

Reiterated

06/10/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)

Justin SmithBernstein

Bernstein

2,290p

Buy

64.22%

Upside

Reiterated

06/04/25

Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)

Kerry HolfordBerenberg Bank

Berenberg Bank

1,600p

Hold

14.74%

Upside

Downgraded

06/02/25

Berenberg Bank downgrades GlaxoSmithKline (GSK) to a Hold

Emily FieldBarclays

Barclays

1,450p

Hold

3.98%

Upside

Reiterated

05/15/25

Barclays Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Sarita KapilaMorgan Stanley

Morgan Stanley

14.5p→1,355p

Sell

-2.83%

Downside

Reiterated

05/07/25

GSK price target lowered to 1,355 GBp from 1,450 GBp at Morgan StanleyGSK price target lowered to 1,355 GBp from 1,450 GBp at Morgan Stanley

Graham ParryBank of America Securities

Bank of America Securities

1,510p

Sell

8.28%

Upside

Reiterated

04/30/25

GlaxoSmithKline Faces Sell Rating Amid EPS Decline and Pipeline Concerns

David EvansKepler Capital

Kepler Capital

1,500p

Hold

7.57%

Upside

Reiterated

04/30/25

GlaxoSmithKline (GSK) Gets a Hold from Kepler Capital

Jo WaltonUBS

UBS

1,600p

Hold

14.74%

Upside

Reiterated

04/30/25

GlaxoSmithKline (GSK) Gets a Hold from UBS

Benjamin Jackson CFAJefferies

Jefferies

1,450p

Hold

3.98%

Upside

Reiterated

04/30/25

Jefferies Remains a Hold on GlaxoSmithKline (GSK)

Unknown AnalystShore Capital

Not Ranked

Shore Capital

―

Buy

―

Reiterated

04/30/25

Rajesh KumarHSBC

HSBC

1,190p→1,170p

Sell

-16.10%

Downside

Reiterated

04/28/25

GSK price target lowered to 1,170 GBp from 1,190 GBp at HSBCGSK price target lowered to 1,170 GBp from 1,190 GBp at HSBC

Peter VerdultExane BNP Paribas

Exane BNP Paribas

1,350p

Hold

-3.19%

Downside

Initiated

04/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

1 Month

xxx

Success Rate

14/27 ratings generated profit

Average Return

-0.61%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 51.85% of your transactions generating a profit, with an average return of -0.61% per trade.

3 Months

xxx

Success Rate

11/21 ratings generated profit

Average Return

-1.28%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of -1.28% per trade.

1 Year

Graham ParryBank of America Securities

Success Rate

12/21 ratings generated profit

Average Return

+0.53%

reiterated a sell rating 2 months ago

Copying Graham Parry's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +0.53% per trade.

2 Years

xxx

Success Rate

12/21 ratings generated profit

Average Return

+1.17%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +1.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GSK Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GSK has received 6 Buy Ratings, 17 Hold Ratings, and 7 Sell Ratings. GSK average Analyst price target in the past 3 months is 1,515.42.

Each month's total comprises the sum of three months' worth of ratings.

GSK Financial Forecast

GSK Earnings Forecast

Next quarter’s earnings estimate for GSK is 0.43p with a range of 0.37p to 0.46p. The previous quarter’s EPS was 0.45p. GSK beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.15% of the time in the same period. In the last calendar year GSK has Outperformed its overall industry.

GSK Sales Forecast

Next quarter’s sales forecast for GSK is 7.85B with a range of 7.72B to 8.05B. The previous quarter’s sales results were 7.52B. GSK beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year GSK has Outperformed its overall industry.

GSK Stock Forecast FAQ

What is GB:GSK’s average 12-month price target, according to analysts?

Based on analyst ratings, GlaxoSmithKline plc (UK)’s 12-month average price target is 1,515.42.

What is GB:GSK’s upside potential, based on the analysts’ average price target?

GlaxoSmithKline plc (UK) has 8.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GlaxoSmithKline plc (UK) a Buy, Sell or Hold?

GlaxoSmithKline plc (UK) has a consensus rating of Hold, which is based on 2 buy ratings, 8 hold ratings and 4 sell ratings.

What is GlaxoSmithKline plc (UK)’s share price target?

The average share price target for GlaxoSmithKline plc (UK) is 1,515.42. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,290.00p ,and the lowest forecast is 1,170.00p. The average share price target represents 8.67% Increase from the current price of 1,394.5p.

What do analysts say about GlaxoSmithKline plc (UK)?

GlaxoSmithKline plc (UK)’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of GlaxoSmithKline plc (UK)?

To buy shares of GB:GSK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

GlaxoSmithKline (GSK) Share Forecast & Price Target

GSK Analyst Ratings

GSK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering GlaxoSmithKline

GSK Analyst Recommendation Trends

GSK Financial Forecast

GSK Earnings Forecast

GSK Sales Forecast

GSK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts